Welcome to our dedicated page for Oramed Pharmaceuticals SEC filings (Ticker: ORMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oramed Pharmaceuticals Inc. (ORMP) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Oramed’s filings reflect its status as a clinical-stage pharmaceutical company and platform technology pioneer in oral delivery solutions for drugs currently delivered via injection, and they document both its operating activities and its capital markets transactions.
Current and periodic reports such as Form 8-K detail material events, including option and warrant agreements, restructuring of notes, joint venture terminations, adoption of a Rights Agreement, and dividend declarations. For example, Oramed has filed 8-K reports describing its Option Agreement for the repurchase of Scilex warrants, restructuring of Scilex debt into convertible notes and warrants, the termination of a joint venture agreement with Hefei Tianhui Biotech Co., Ltd., and the adoption of a Rights Agreement that includes a dividend of common stock purchase rights.
Financial reporting is captured in quarterly and annual filings (Forms 10-Q and 10-K), which include Oramed’s financial statements, management’s discussion and analysis, and notes regarding its oral insulin program, POD™ technology development, and diversified investment portfolio. These documents provide context on how investments in entities such as Scilex Holding Company and Alpha Tau Medical Ltd. are reflected in the company’s financial condition and results of operations.
Filings also cover corporate governance and equity compensation, such as amendments to the company’s stock incentive plan and voting results from annual meetings of stockholders, as well as details on Oramed’s common stock registration on The Nasdaq Capital Market and the Tel Aviv Stock Exchange.
On Stock Titan, AI-powered tools summarize key points from Oramed’s 10-K, 10-Q, and 8-K filings, helping users quickly understand complex disclosures, track changes in financing arrangements, and review material agreements. Investors can also monitor updates related to rights plans and other actions that may affect the rights of security holders.
ORAMED PHARMACEUTICALS INC. reported that Chief Scientific Officer Miriam Kidron received a grant of 119,558 restricted stock units (RSUs) of common stock. These RSUs will vest in eight equal quarterly installments beginning on April 1, 2026, providing staged equity-based compensation over two years.
Each RSU represents the right to receive one share of common stock with a par value of $0.012 per share. Following this award, Kidron’s reported direct holdings increased to 1,568,222 shares of common stock, indicating this is a sizable but compensation-related, non-cash acquisition rather than an open-market purchase.
KIDRON NADAV reported acquisition or exercise transactions in this Form 4 filing.
Oramed Pharmaceuticals reported that President and CEO Nadav Kidron received a grant of 167,005 Restricted Stock Units (RSUs) of common stock at no cash cost. The award increases his direct holdings to 3,422,243 shares after the transaction.
The RSUs will vest in eight equal quarterly installments beginning April 1, 2026, aligning a portion of the CEO’s compensation with the company’s long-term performance. Each RSU represents the right to receive one share of Oramed common stock as it vests.
Hexter Joshua reported acquisition or exercise transactions in this Form 4 filing.
ORAMED PHARMACEUTICALS INC. reported that its COO & CBO, Joshua Hexter, received a grant of 95,889 shares of Common Stock in the form of Restricted Stock Units. These RSUs will vest in eight equal quarterly installments beginning on April 1, 2026, with each RSU delivering one share upon vesting. Following this award, Hexter directly holds a total of 1,160,384 shares of the company’s common stock, reflecting a compensation-related equity grant rather than an open-market purchase.
Oramed Pharmaceuticals Chief Financial Officer Avraham Gabay received an equity grant of 95,889 Restricted Stock Units (RSUs). The RSUs vest in eight equal quarterly installments beginning on April 1, 2026, encouraging longer-term retention. Each RSU converts into one share of common stock when it vests, bringing his direct holdings to 745,145 shares after the award.
ORAMED PHARMACEUTICALS INC. President and CEO Nadav Kidron reported a bona fide charitable gift of 100,000 shares of Common Stock on March 12, 2026. The filing states this was a charitable donation, not a market transaction, and no value was received for the shares.
Following the donation, Kidron directly holds 3,255,238 shares of Oramed common stock. The footnote further explains that he is not affiliated with, and has no control over, the charitable donee, underscoring that this is a non-economic transfer rather than a sale in the open market.
Oramed Pharmaceuticals Inc. entered into a new warrant agreement with Scilex Holding Company on February 19, 2026. In return for previously deferring an amortization payment on Scilex’s senior secured convertible Tranche B Notes, Oramed received a February 2026 warrant to purchase 100,000 shares of Scilex common stock at an initial exercise price of $20.00 per share.
The warrant is immediately exercisable and expires on December 13, 2029. Its exercise price is adjustable for stock splits and certain future offerings, but not below a floor price of $8.22. The warrant includes a beneficial ownership cap of 4.99%, which Oramed may raise up to 9.99% with 61 days’ notice. It also contains protections in change-of-control and other fundamental transactions, including a right for Oramed to require cash repurchase of the unexercised portion at its Black Scholes value.
BML Investment Partners, L.P. and Braden M. Leonard filed an amended Schedule 13G disclosing a significant stake in Oramed Pharmaceuticals Inc. Leonard reports beneficial ownership of 3,287,531 shares of common stock, representing 8.3% of the class, including 120,300 shares over which he has sole voting and dispositive power and 3,167,231 shares with shared power.
The filing states these securities are not held for the purpose of changing or influencing control of Oramed, and the reporting persons disclaim that they form a statutory group.
Oramed Pharmaceuticals executive Joshua Hexter reported a share-based award vesting. On January 22, 2026, 19,000 performance stock units vested after Oramed’s common stock reached a specified price target. Each unit converted into one common share, giving Hexter 19,000 shares received for no cash consideration.
Following this conversion, Hexter directly holds 1,064,495 shares of Oramed common stock. The performance stock units were granted on December 31, 2025, and no derivative units of this grant remain outstanding after the vesting.
Oramed Pharmaceuticals (ORMP) director and Chief Scientific Officer Miriam Kidron reported the vesting of performance stock units (PSUs) into common shares. On January 22, 2026, 19,000 PSUs vested after Oramed’s common stock reached a specified price level.
Each PSU converted into one share of common stock, so Kidron received 19,000 shares of Oramed common stock for no cash consideration. Following this equity-based award, she directly beneficially owns 1,448,664 shares of Oramed common stock, reflecting her ongoing equity stake in the company.
Oramed Pharmaceuticals Inc. Chief Financial Officer Avraham Gabay reported the vesting of 19,000 performance stock units into common shares. The PSUs were granted on December 31, 2025 and vested on January 22, 2026 after Oramed’s common stock reached a specified price per share.
Each PSU converted into one share of common stock, and the shares were received for no cash consideration. Following this transaction, Gabay directly beneficially owns 649,256 shares of Oramed common stock.